Ciphergen Biosystems developed a unique technology, using a patented protein chip to detect proteins within biological samples. The technology proved efficient and cost-effective. Ciphergen customers included many of the largest pharmaceutical and biotechnology companies worldwide, as well as government agencies, research institutions and universities. Working with customers to develop new products and applications, Ciphergen became a leader in biomarker discovery, assay development and characterisation.
Amadeus invested in Ciphergen in its $29 million pre-IPO financing round in March 2000. The company successfully floated on NASDAQ.